Organon & Co. Sees Unusually High Options Volume (NYSE:OGN)

Organon & Co. (NYSE:OGN) saw some unusual options trading activity on Tuesday. Investors purchased 17,794 call options on the company. This represents an increase of 550% compared to the typical daily volume of 2,737 call options.

Organon & Co. Stock Performance

Shares of NYSE:OGN opened at $8.20 on Thursday. The company has a current ratio of 1.75, a quick ratio of 1.20 and a debt-to-equity ratio of 9.69. Organon & Co. has a 12 month low of $6.18 and a 12 month high of $17.23. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of 4.27, a PEG ratio of 1.67 and a beta of 0.58. The firm’s 50-day moving average is $7.24 and its 200 day moving average is $8.85.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Monday, November 10th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.08. The business had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. During the same quarter last year, the firm earned $1.38 earnings per share. Research analysts predict that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 11th. Shareholders of record on Thursday, November 20th were given a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend was Thursday, November 20th. Organon & Co.’s dividend payout ratio is 4.17%.

Analyst Ratings Changes

OGN has been the topic of several research reports. Morgan Stanley reduced their target price on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. JPMorgan Chase & Co. decreased their price objective on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a report on Tuesday, November 11th. Wall Street Zen upgraded Organon & Co. from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, Barclays started coverage on shares of Organon & Co. in a report on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 target price for the company. One research analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $8.38.

Institutional Trading of Organon & Co.

Several institutional investors and hedge funds have recently made changes to their positions in OGN. Ransom Advisory Ltd bought a new position in shares of Organon & Co. in the first quarter worth about $32,000. Hanson & Doremus Investment Management purchased a new stake in Organon & Co. in the 2nd quarter valued at about $26,000. Hantz Financial Services Inc. grew its stake in Organon & Co. by 293.8% in the 2nd quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company’s stock worth $26,000 after acquiring an additional 1,995 shares in the last quarter. Foster Dykema Cabot & Partners LLC purchased a new position in shares of Organon & Co. during the third quarter worth approximately $29,000. Finally, Rothschild Investment LLC increased its position in shares of Organon & Co. by 73.1% during the third quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock worth $42,000 after acquiring an additional 1,646 shares during the period. 77.43% of the stock is currently owned by institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.